Connetics
Woolston
About Connetics
Connetics Corporation engages in the development and commercialization of products for the medical dermatology market. The company markets two products, Luxiq and OLUX, both of which use the company's proprietary foam delivery system. Luxiq is considered as the company’s first dermatology product and OLUX treat psoriasis of the scalp. The products are classified as topical steroids. Luxiq competes in the mid-potency category of the topical steroids market and OLUX competes in the high- and super-high potency category of the topical steroids market. Connetics also owns the rights to Soriatane, an oral psoriasis drug originally developed by Switzerland-based La Roche Holding. Connetics follows what it refers to as its ""4:2:1"" development model, a strategy that calls for the company to have four products in development, two products in final stage trials mandated by the Food and Drug Administration (FDA), and one new FDA-approved product every year. Connetics Corporation was formerly known as Connective Therapeutics, Inc. It was incorporated in 1993 and is headquartered in Palo Alto, California.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 501 – 1,000
- Estimated revenue: $10K – $50K
- Website: connetics.co.nz
- Phone: +64 3 353 7200
Social Profiles
Canonical: https://fsome.com/organization/connetics-2810105 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.